236 related articles for article (PubMed ID: 1447717)
21. [Novel approach of cyclodextrin-based pharmaceutical formulation].
Uekama K
Yakugaku Zasshi; 2012; 132(1):85-105. PubMed ID: 22214584
[TBL] [Abstract][Full Text] [Related]
22. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
23. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
24. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
Mady FM; Farghaly Aly U
Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
[TBL] [Abstract][Full Text] [Related]
25. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
[TBL] [Abstract][Full Text] [Related]
26. Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits.
Jarho P; Järvinen K; Urtti A; Stella VJ; Järvinen T
J Pharm Pharmacol; 1996 Mar; 48(3):263-9. PubMed ID: 8737051
[TBL] [Abstract][Full Text] [Related]
27. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
28. Effect of cyclodextrins on biological membrane. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins.
Nakanishi K; Nadai T; Masada M; Miyajima K
Chem Pharm Bull (Tokyo); 1992 May; 40(5):1252-6. PubMed ID: 1394642
[TBL] [Abstract][Full Text] [Related]
29. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone.
Lopez RF; Collett JH; Bentley MV
Int J Pharm; 2000 Apr; 200(1):127-32. PubMed ID: 10845694
[TBL] [Abstract][Full Text] [Related]
30. A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats.
Vollmer U; Müller BW; Peeters J; Mesens J; Wilffert B; Peters T
J Pharm Pharmacol; 1994 Jan; 46(1):19-22. PubMed ID: 8201522
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies.
Nagase Y; Arima H; Wada K; Sugawara T; Satoh H; Hirayama F; Uekama K
J Pharm Sci; 2003 Dec; 92(12):2466-74. PubMed ID: 14603492
[TBL] [Abstract][Full Text] [Related]
32. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
Sharma US; Balasubramanian SV; Straubinger RM
J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
[TBL] [Abstract][Full Text] [Related]
34. Effect of sugar-modified beta-cyclodextrins on dissolution and absorption characteristics of phenytoin.
Tanino T; Ogiso T; Iwaki M
Biol Pharm Bull; 1999 Mar; 22(3):298-304. PubMed ID: 10220288
[TBL] [Abstract][Full Text] [Related]
35. Biomembrane model interaction and percutaneous absorption of papaverine through rat skin: effects of cyclodextrins as penetration enhancers.
Ventura CA; Fresta M; Paolino D; Pedotti S; Corsaro A; Puglisi G
J Drug Target; 2001; 9(5):379-93. PubMed ID: 11770707
[TBL] [Abstract][Full Text] [Related]
36. Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives.
Ikeda Y; Kimura K; Hirayama F; Arima H; Uekama K
J Control Release; 2000 May; 66(2-3):271-80. PubMed ID: 10742586
[TBL] [Abstract][Full Text] [Related]
37. [Pharmaceutical application of cyclodextrins as multi-functional drug carriers].
Uekama K
Yakugaku Zasshi; 2004 Dec; 124(12):909-35. PubMed ID: 15577263
[TBL] [Abstract][Full Text] [Related]
38. Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats.
Tokihiro K; Arima H; Tajiri S; Irie T; Hirayama F; Uekama K
J Pharm Pharmacol; 2000 Aug; 52(8):911-7. PubMed ID: 11007061
[TBL] [Abstract][Full Text] [Related]
39. Influence of hydroxypropyl beta-cyclodextrin on the stability of benzylpenicillin in chloroacetate buffer.
Ong JK; Sunderland VB; McDonald C
J Pharm Pharmacol; 1997 Jun; 49(6):617-21. PubMed ID: 9330202
[TBL] [Abstract][Full Text] [Related]
40. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats.
Nagarsenker MS; Meshram RN; Ramprakash G
J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
